World's Best Scientists 2026 revealed!
Hyun Cheol Chung

Hyun Cheol Chung

D-Index & Metrics

Medicine

D-Index
90
Citations
59181
World Ranking
11948
National Ranking
36

Overview

Hyun Cheol Chung is affiliated with Yonsei University in South Korea and has contributed extensively to the field of medicine, with a focus on oncology. Their research spans multiple subfields including oncology, pulmonary and respiratory medicine, surgery, gastroenterology, and molecular biology.

The main topics addressed in their work encompass gastric cancer management and outcomes, cancer immunotherapy and biomarkers, colorectal cancer treatments and studies, HER2/EGFR in cancer research, gastrointestinal tumor research and treatment, esophageal cancer research and treatment, and pancreatic and hepatic oncology research.

Frequent coauthors collaborating with Hyun Cheol Chung include:

  • Sun Young Rha
  • Kohei Shitara
  • Minkyu Jung
  • Woo Sun Kwon
  • Yung-Jue Bang

They have published papers in various venues, with notable frequent publication venues being:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Gastric Cancer
  • memo - Magazine of European Medical Oncology

Selected recent papers by Hyun Cheol Chung include:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020, The Lancet Oncology)
  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer (2020, New England Journal of Medicine)
  • Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer (2020, JAMA Oncology)
  • Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial (2022, The Lancet Oncology)
  • The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer (2021, Nature)

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

    Aurelien Marabelle;Dung T. Le;Paolo A. Ascierto;Anna Maria Di Giacomo

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

    Yung Jue Bang;Young Woo Kim;Han Kwang Yang;Hyun Cheol Chung

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    Kei Muro;Hyun Cheol Chung;Veena Shankaran;Ravit Geva

  • Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.

    Sung Hoon Noh;Sook Ryun Park;Han Kwang Yang;Hyun Cheol Chung

  • Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

    Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  • Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Laura Q.M. Chow;Robert Haddad;Shilpa Gupta;Amit Mahipal

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

    Kohei Shitara;Yung-Jue Bang;Satoru Iwasa;Naotoshi Sugimoto

  • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

    Florian Lordick;Yoon Koo Kang;Hyun Cheol Chung;Pamela Salman

  • Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.

    Hyun Cheol Chung;Willeke Ros;Jean Pierre Delord;Ruth Perets

  • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

    Jeong Heo;Tony Reid;Leyo Ruo;Caroline J. Breitbach

  • Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

    Kohei Shitara;Eric Van Cutsem;Yung Jue Bang;Charles Fuchs

  • Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    Ann Lii Cheng;Yoon Koo Kang;Deng Yn Lin;Joong Won Park

  • Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study

    Taroh Satoh;Rui-Hua Xu;Hyun Cheol Chung;Guo-Ping Sun

  • Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

    Eva S. Thomas;Henry L. Gomez;Rubi K. Li;Hyun Cheol Chung

  • Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

    Keun Seok Lee;Hyun Cheol Chung;Seock Ah Im;Yeon Hee Park

  • Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study

    Atsushi Ohtsu;Jaffer A. Ajani;Yu Xian Bai;Yung Jue Bang

Frequent Co-Authors

Sun Young Rha
Sun Young Rha Yonsei University
Sung Hoon Noh
Sung Hoon Noh Yonsei University
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Kei Muro
Kei Muro National Cancer Research Institute, UK
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Woo Jin Hyung
Woo Jin Hyung Yonsei University
Jeeyun Lee
Jeeyun Lee Sungkyunkwan University
Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in healthcare beyond medicine? There are many online degree options to help you expand your expertise or transition into new healthcare roles. Online programs offer flexible schedules and the opportunity to learn from anywhere, making them popular among working professionals and students alike.

Advanced nursing roles are in high demand, especially in mental health. If you're interested in the fastest routes to become a nurse practitioner, explore these pmhnp online programs. For those looking to impact healthcare systems and policy, a Master of Healthcare Administration (MHA) can open diverse career opportunities. Affordability is key, so consider the cheapest mha programs online and learn more about the actual cost of mha degree.

Additionally, for nurses aiming for the highest level of clinical practice, there are options to pursue the cheapest dnp programs to enhance your qualifications without breaking the bank. No matter your interest, online healthcare degrees present flexible pathways to boost your career and support the evolving needs of the medical field.

Best Scientists Citing Hyun Cheol Chung

Trending Scientists